Industry & Competitor Analysis BUS 630 – Spring 2008 Instructor: Email: Office Hrs: Course page: Russell Coff (www.bus.emory.edu/rcoff/) Russ_Coff@bus.emory.edu by appointment www.bus.emory.edu/rcoff/Bus630.html Phone: (404) 727-0526 FAX: (404) 727-6313 Revised 1/22/08 Course Overview and Objectives This course delves deeper into some strategy topics that you may have only touched upon earlier related to how firms gain a competitive advantage over rivals. In addition, since ICA tends to integrate
Words: 7898 - Pages: 32
license and provide funding for a newly developed drug compound called Davanrik. If Merck, the licensee purchased the compound it would be responsible for the design, administration, and funding of the clinical testing of the compound, as well as take care of its manufacturing and marketing. LAB the licensor would receive an initial payment followed by additional payments as Davanrik completes each clinical testing phase. Davanrik was initially developed to treat depression but during the pre-clinical
Words: 592 - Pages: 3
initial investment no matter whether Davanrik will get approved by FDA in future. In Phase 2, Merck has to pay LAB 2.5 million Milestone payment if Davanrik successfully complete Phase 1 with a probability of 60%. In Phase 3, the amount of milestone payment Merck has to pay depends on the result of Phase 2. If Davanrik successfully complete phase 2 and was effective only for depression with the probability of 10%, then Merck has to pay 20 million to LAB. If Davanrik successfully complete phase 2 and
Words: 406 - Pages: 2
team to decide whether his company should license Davanrik, a new drug with the potential to treat both depression and obesity. The small pharmaceutical concern that developed the drug, LAB Pharmaceuticals, lacked the resources to complete the lengthy approval process, manufacture the compound, and market the drug. LAB had approached Merck with an offer to license the compound. Under this agreement, Merck would be responsible for the approval of Davanrik, its manufacture, and its marketing. The company
Words: 2360 - Pages: 10
Drug Licensing Opportunity Statement of the problem- Merck must determine whether or not to bid to license Davanrik My recommendation is that Merck must definitely make a competitive bid for Davanrik. The total expected value from the deal based numbers given in the Merck article is a healthy $14million so keeping a 20% incentive, Merck should bid no more than $11million for Davanrik as the initial licensing fee. Looking at the background of Merck, it is clear that it is a successful company
Words: 721 - Pages: 3
3. Should Merck bid to license Davanrik? How much should they pay? Our team will recommend Merck bid to license Davanrik given the following reasons: 1. One of the major advantage of the company is its patents of new drugs. According to the case, we know that four drugs will expire by 2002 and those drugs are regarded as the so-called star-products of the company. According to the company’s financial statement, we learn that Merck’s net income margin has declined from 19.52% to 18% and the research
Words: 545 - Pages: 3
Summary Statement of the Problem LAB Pharmaceuticals does not have enough capital to finance the testing of Davanrik, an antidepressant drugs that has potential side effects relating to obesity. LAB approaches Merck & Co., Inc. (Merck) and asks the company to license Davanrik, as well as funding the clinical testing. Merck must decide whether or not to bid to license Davanrik and if so, at what price. Discussion Merck is facing patent expiration problem because most of its popular drugs
Words: 1593 - Pages: 7
current opportunity that Merck and Company is being presented with we have come up with the following recommendations on how best for you and your company to proceed with this proposal to purchase LAB Pharmaceuticals new drug, Davanrik. We feel that purchasing the rights to Davanrik is a great opportunity for Merck and Company to expand its product portfolio, customer base and future revenues. That being said, there are risks associated with taking on the costly and lengthy FDA approval processes that
Words: 2390 - Pages: 10
Should Rich Kender recommend licensing Davanrik, making Merck & Company responsible for its manufacture and its marketing? In order to provide Rich Kender with a good and thorough analysis and recommendation on the Davanrik licensing project, we need to answer the following guidance questions: I. How has Merck been able to achieve substantial returns to capital given the large costs and lengthy time to develop drugs? II. How much should they pay? III. What is the expected value of the
Words: 315 - Pages: 2
company, such as Merck, which has more resources and money. 2. Build a decision-tree that shows the cash flows and probabilities at all stages of the FDA approval process. Since the EMV of the decision tree is positive, Merck should license Davanrik. From consolidated income statement, we could calculate the retained earnings as a percentage of income before taxes. 23447.9−20186.7 X 100=37.84
Words: 658 - Pages: 3
